Status: Not yet recruiting
Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI
A Prospective Study of Zorifertinib Combined with Intra-Ommaya Reservoir Cerebrospinal Fluid Chemotherapy for Leptomeningeal Progression in NSCLC Patients After Third-Generation EGFR-TKI Therapy
Participants needed: 38
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesUpdated: Apr 24, 2026Locations: 1
Eligibility criteria
1. Have fully understood the study and voluntarily signed the Informed Consent F... [+7]
1. Subjects with a history of cranial or spinal radiotherapy within 6 months pri... [+9]